drugset / Trial / NCT00499252

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT00499252 ↗

NaSingle-groupOpen-labelTreatment

Summary

This phase II trial is studying the side effects and how well paclitaxel albumin-stabilized nanoparticle formulation works in treating patients with recurrent or persistent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

Timeline

Start
2007-06
Primary completion
2011-07
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Paclitaxel Small molecule — Intravenous